<DOC>
	<DOC>NCT02344017</DOC>
	<brief_summary>The purpose of this first-in-man study is to evaluate safety, tolerability and pharmacokinetics of ODM-204 in patients with metastatic castration-resistant prostate cancer.</brief_summary>
	<brief_title>Safety and Pharmacokinetics of ODM-204 in Patients With Metastatic Castration-Resistant Prostate Cancer</brief_title>
	<detailed_description>The safety profile of ODM-204 will be explored together with the pharmacokinetics, pharmacodynamics and tumour response to treatment with ODM-204 to recommend the dosing regimen for further clinical studies. The pharmacokinetic properties of ODM-204 will be evaluated after single and multiple dose administrations at different dose levels.</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<criteria>Written informed consent (IC) obtained. Male aged â‰¥ 18 years. Histologically or cytologically confirmed adenocarcinoma of prostate. Ongoing GnRH agonist or antagonist therapy, or after bilateral orchiectomy. Progressive metastatic disease Adequate bone marrow, hepatic, and renal function Acceptable and regular bowel movements without any GI disorder or procedure which may interfere with absorption of study treatment Ability to swallow study treatments History of pituitary or adrenal dysfunction. Known brain metastases. Active infection or other medical condition that would make prednisone (corticosteroid) contraindicated. Uncontrolled hypertension Clinically significant heart disease Prolonged QTc interval</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>